Retinal Vein Occlusion – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Retinal Vein Occlusion – Pipeline Review, H2 2016’, provides an overview of the Retinal Vein Occlusion pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion

The report reviews pipeline therapeutics for Retinal Vein Occlusion by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Retinal Vein Occlusion therapeutics and enlists all their major and minor projects

The report assesses Retinal Vein Occlusion therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Retinal Vein Occlusion

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Retinal Vein Occlusion pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aerpio Therapeutics, Inc.

Clearside BioMedical, Inc.

Formycon AG

Kala Pharmaceuticals, Inc.

Mabion SA

NicOx S.A.

Ohr Pharmaceutical Inc.

Precision Ocular Ltd

ThromboGenics NV

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Retinal Vein Occlusion Overview 7

Therapeutics Development 8

Pipeline Products for Retinal Vein Occlusion - Overview 8

Retinal Vein Occlusion - Therapeutics under Development by Companies 9

Retinal Vein Occlusion - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Retinal Vein Occlusion - Products under Development by Companies 13

Retinal Vein Occlusion - Companies Involved in Therapeutics Development 14

Aerpio Therapeutics, Inc. 14

Clearside BioMedical, Inc. 15

Formycon AG 16

Kala Pharmaceuticals, Inc. 17

Mabion SA 18

NicOx S.A. 19

Ohr Pharmaceutical Inc. 20

Precision Ocular Ltd 21

ThromboGenics NV 22

Retinal Vein Occlusion - Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Combination Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

(aflibercept + triamcinolone acetonide) - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

aflibercept biosimilar - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

AKB-9778 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

HO-10 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

LKA-651 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

loteprednol etabonate - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

NCX-422 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

NCX-434 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

ocriplasmin - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

ranibizumab biosimilar - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

ranibizumab biosimilar - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecule for Ophthalmology and Orphan Diseases - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

squalamine lactate - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Retinal Vein Occlusion - Dormant Projects 66

Retinal Vein Occlusion - Discontinued Products 67

Retinal Vein Occlusion - Product Development Milestones 68

Featured News & Press Releases 68

Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting 68

Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion 68

Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion 69

Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration 70

Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion 70

Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion 71

Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion 72

Jul 31, 2014: Kala Pharmaceuticals Initiates Phase 2 Clinical Trial to Evaluate LE-MPP (KPI-121) in Patients with Retinal Vein Occlusion and Diabetic Macular Edema 73

Aug 20, 2013: Ohr Pharmaceutical Announces Investigator Sponsored Trial of Squalamine Eye Drops in Retinal Vein Occlusion 74

Appendix 75

Methodology 75

Coverage 75

Secondary Research 75

Primary Research 75

Expert Panel Validation 75

Contact Us 75

Disclaimer 76

List of Tables

List of Tables

Number of Products under Development for Retinal Vein Occlusion, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Retinal Vein Occlusion – Pipeline by Aerpio Therapeutics, Inc., H2 2016 14

Retinal Vein Occlusion – Pipeline by Clearside BioMedical, Inc., H2 2016 15

Retinal Vein Occlusion – Pipeline by Formycon AG, H2 2016 16

Retinal Vein Occlusion – Pipeline by Kala Pharmaceuticals, Inc., H2 2016 17

Retinal Vein Occlusion – Pipeline by Mabion SA, H2 2016 18

Retinal Vein Occlusion – Pipeline by NicOx S.A., H2 2016 19

Retinal Vein Occlusion – Pipeline by Ohr Pharmaceutical Inc., H2 2016 20

Retinal Vein Occlusion – Pipeline by Precision Ocular Ltd, H2 2016 21

Retinal Vein Occlusion – Pipeline by ThromboGenics NV, H2 2016 22

Assessment by Monotherapy Products, H2 2016 23

Assessment by Combination Products, H2 2016 24

Number of Products by Stage and Target, H2 2016 26

Number of Products by Stage and Mechanism of Action, H2 2016 28

Number of Products by Stage and Route of Administration, H2 2016 30

Number of Products by Stage and Molecule Type, H2 2016 32

Retinal Vein Occlusion – Dormant Projects, H2 2016 66

Retinal Vein Occlusion – Discontinued Products, H2 2016 67

List of Figures

List of Figures

Number of Products under Development for Retinal Vein Occlusion, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Top 10 Targets, H2 2016 25

Number of Products by Stage and Top 10 Targets, H2 2016 25

Number of Products by Top 10 Mechanism of Actions, H2 2016 27

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 27

Number of Products by Routes of Administration, H2 2016 29

Number of Products by Stage and Routes of Administration, H2 2016 29

Number of Products by Molecule Types, H2 2016 31

Number of Products by Stage and Molecule Types, H2 2016 31

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports